Trump admin seeks to roll back testosterone restrictions: what to know

Key Points:

• The Department of Health and Human Services (HHS) is seeking to update testosterone replacement therapy (TRT) prescribing information to ease access for older men, reversing earlier FDA warnings about cardiovascular risks and prostate concerns.
• The 2015 FDA warnings cited potential heart attack and stroke risks from TRT, but new research, including the 2023 TRAVERSE trial of over 5,200 men, found no increase in major cardiac events compared to placebo, though some risks like atrial fibrillation and pulmonary embolism remain uncertain.
• HHS proposes relaxing prostate cancer-related restrictions, limiting TRT contraindications to metastatic prostate cancer only, based on evidence that TRT does not increase prostate cancer risk in men without existing disease, while still recommending careful patient screening and monitoring.
• Labeling updates are also requested for benign prostatic hyperplasia (BPH), with current warnings being softened to advise ongoing monitoring during TRT, as evidence shows TRT does not worsen symptoms in mild to moderate BPH but effects in severe cases are unclear.
• Experts remain divided on TRT safety, emphasizing the need for further research, but HHS officials stress that updated labels will provide clearer, science-based guidance to improve informed decision-making for patients and physicians.